Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Ahmed M ShamanStephen C BainGeorge L BakrisJohn B BuseThomas IdornKenneth W MahaffeyJohannes F E MannMichael A NauckSøren RasmussenPeter RossingBenjamin WolthersBernard ZinmanVlado PerkovicPublished in: Circulation (2021)
In patients with type 2 diabetes, semaglutide/liraglutide offered kidney-protective effects, which appeared more pronounced in patients with preexisting chronic kidney disease.